Unknown

Dataset Information

0

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.


ABSTRACT: The improvement in outcomes of adult patients with acute lymphoblastic leukemia (ALL) has been modest, with the exception of Philadelphia chromosome-positive disease, despite advances in supportive care and stem cell transplantation. The recent approvals of novel agents, including the bispecific T-cell engager blinatumomab, the antibody-drug conjugate inotuzumab ozogamicin, and chimeric antigen receptor T-cell products are changing the management of B-ALL, which traditionally relied on chemotherapy-based approaches. Inotuzumab ozogamicin is a humanized CD22 monoclonal antibody linked to the cytotoxic agent calicheamicin. CD22 is expressed on leukemic blasts in >90% of ALL patients, and inotuzumab ozogamicin has shown excellent clinical activity even among heavily pretreated relapsed/refractory (R/R) B-ALL patients and elderly B-ALL patients. Clinical trials have shown superior survival with the drug over chemotherapy-based approaches in the first- or second-line salvage therapy for relapsed B-ALL as monotherapy. Currently, new trials are evaluating inotuzumab ozogamicin in the frontline setting in combination-based approaches. In this review, we summarize the preclinical and clinical data of inotuzumab ozogamicin in R/R B-ALL and foresee the future use of this drug in the clinic.

SUBMITTER: Uy N 

PROVIDER: S-EPMC5908210 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.

Uy Natalie N   Nadeau Michelle M   Stahl Maximilian M   Zeidan Amer M AM  

Journal of blood medicine 20180413


The improvement in outcomes of adult patients with acute lymphoblastic leukemia (ALL) has been modest, with the exception of Philadelphia chromosome-positive disease, despite advances in supportive care and stem cell transplantation. The recent approvals of novel agents, including the bispecific T-cell engager blinatumomab, the antibody-drug conjugate inotuzumab ozogamicin, and chimeric antigen receptor T-cell products are changing the management of B-ALL, which traditionally relied on chemother  ...[more]

Similar Datasets

| S-EPMC6822860 | biostudies-other
| S-EPMC6438769 | biostudies-literature
| S-EPMC6238377 | biostudies-literature
| S-EPMC7414105 | biostudies-literature
| S-EPMC6529376 | biostudies-literature
| S-EPMC6063246 | biostudies-literature
| S-EPMC7992772 | biostudies-literature
| S-EPMC7995290 | biostudies-literature
| S-EPMC5728308 | biostudies-literature
| S-EPMC5594743 | biostudies-literature